Clinical trial · Interventional
Time Restricted Eating in Survivors Trial 2.0
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
After chemotherapy, older breast cancer survivors experience a faster decline in brain function. This can make it harder to enjoy life, stay social, and maintain independence. Chemotherapy can lead to poorer lifestyle habits, like unhealthy eating, less exercise, high stress, and poor sleep. Chemotherapy can also affect important health markers like blood sugar and cholesterol. Over time, these changes can damage blood vessels, which might lead to heart and brain issues. The investigators do not fully understand why brain function declines faster after chemotherapy, especially in older survivors, because there are many factors involved. In this study, the investigators will look at how lifestyle habits (like diet, exercise, stress and sleep), health markers (like blood sugar and cholesterol), and blood vessel health (like how well blood flows and how stiff the blood vessels are) affect brain function in older breast cancer survivors. The investigators will include 152 females aged 60-85 years, who finished chemotherapy for early-stage breast cancer at least 1 year ago. The investigators will use special tests to check different parts of brain function, like language, memory, and attention, as well as brain blood vessel health. This will help to understand which factors might speed up or slow down memory and thinking problems. Since many Canadian breast cancer survivors experience faster decline in brain function after chemotherapy, this study aims to find out what might make it worse. The results could help to create better and more personalized treatment plans for older breast cancer survivors that protect brain health and reduce problems with brain function in the future.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cardiovascular Risk | — | UNRESOLVED | — |
| Cognitive Function | — | UNRESOLVED | — |
| Physical Function | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Healthy Eating Education | Behavioral | — | UNRESOLVED |
| Time Restricted Eating | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Time Restricted Eating
- description
- The TRE group will be asked to restrict the time they consume food to an 8-h window starting at any time of the day and ending ≥3-h before bed, every day for 16 weeks.
- interventionNames
- Behavioral: Time Restricted Eating
- type
- ACTIVE_COMPARATOR
- label
- Healthy Eating Education
- description
- The healthy eating education group will be asked not to make major changes to the timing or number of meals they consume every day for 16 weeks.
- interventionNames
- Behavioral: Healthy Eating Education
Primary outcomes (1)
- measure
- Framingham Risk Score (10-year)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 60 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * female * aged 60-85 years * BMI ≥25 kg/m2 * diagnosed with early-stage (I-III) BC in the past 15 years * received chemotherapy treatment that was completed ≥1 year earlier * Montreal Cognitive Assessment (MoCA) score of 10-30 which aligns with no impairment to moderate impairment thresholds. Exclusion Criteria: * does not have a mobile device that connects to Bluetooth and can send/receive text messages * history of physician-diagnosed heart disease, dementia or Alzheimer's disease, diabetes that requires insulin or sulfonylurea usage, or eating disorder * MoCA total score \<10 (indicating dementia) * ≥5kg weight change within past 3 months * taking lipid- or weight-lowering medication (e.g. statins or GLP-1 agonists) * high-risk for malnutrition (≥3 on the Malnutrition Screening Tool) * research MRI contraindications (e.g., pacemaker, breast tissue expander, magnetic implants) * eating all daily calories in \<10h/d in the past 3 months * following a structured dietary practice (e.g., ketogenic diet, Weight Watchers) or actively trying to lose weight in the past 3 months * being unable to make adjustments to eating time or nutrient intake * regularly doing \>90 min/week of moderate physical activity in the past 3 months * severe claustrophobia * BMI\>40 kg/m2 (due to body habitus fit within MRI scanner bore) * major psychiatric disorders (e.g. bipolar, post-traumatic stress disorder, schizophrenia) * neurological disorders that significantly impact physical or cognitive function (epilepsy, stroke, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, muscular dystrophy) or traumatic brain injury resulting in ongoing neurological deficits. If the screening process identifies patients with undiagnosed severe cognitive function (MoCA score \<10) or at high risk for malnutrition (≥3 on the Malnutrition Screening Tool), the investigators will recommend that the individual see their family physician. In this process, the investigators will ask the participant if there is a family member that can also receive this information.
References
Publications (0)
Data not yet available